MARKET

JNJ

JNJ

Johnson & Johnson
NYSE
165.62
+2.42
+1.48%
After Hours: 165.62 0 0.00% 16:14 10/04 EDT
OPEN
163.85
PREV CLOSE
163.20
HIGH
166.00
LOW
162.92
VOLUME
6.17M
TURNOVER
0
52 WEEK HIGH
186.69
52 WEEK LOW
152.84
MARKET CAP
435.44B
P/E (TTM)
24.08
1D
5D
1M
3M
1Y
5Y
Johnson & Johnson stock rises Tuesday, still underperforms market
marketwatch.com · 28m ago
DEA-Licensed Pharmaceutical Cannabis Research Company Announces $20M Series A Funding Round
The Biopharmaceutical Research Company (BRC), an active DEA pharmaceutical cannabis license holder, announced the completion of a $20 million Series A fundraise, that will enable the company to scale its operations and increase its product offering, conduct sponsored research, and execute on its go-to-market strategy.
Benzinga · 3h ago
The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short
The stock market has had a rough going for the first nine months of the year in 2022. All the major indexes are down year-to-date, including the Dow Jones Industrial Average. Here’s a look at the four stocks in the index that have posted positive gains in 2022.
Benzinga · 23h ago
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed at $163.20 in the latest trading session, marking a -0.1% move from the prior day.
Zacks · 23h ago
Johnson & Johnson stock falls Monday, underperforms market
marketwatch.com · 1d ago
Johnson & Johnson to Participate in the Credit Suisse 31st Annual Healthcare Conference
NEW BRUNSWICK, N.J., October 03, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 31st Annual Global Healthcare Conference on Thursday, November 10th, 2022 at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Execut...
Business Wire · 1d ago
UBS Adjusts Johnson & Johnson Price Target to $175 From $180, Maintains Neutral Rating
UBS Adjusts Johnson & Johnson Price Target to $175 From $180, Maintains Neutral Rating
MT Newswires · 1d ago
BRIEF-U.S. CDC Says As Of Sept 28, 3.2 Mln People Received An Updated Booster Dose For Covid-19 Vaccine Since Sept 21
BRIEF-U.S. CDC Says As Of Sept 28, 3.2 Mln People Received An Updated Booster Dose For Covid-19 Vaccine Since Sept 21
Reuters · 4d ago
More
About JNJ
Johnson & Johnson is a holding company that is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.

Webull offers kinds of Johnson & Johnson stock information, including NYSE:JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.